Skilled Care Journal – The FDA’s recent approval of Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD) marks a significant development with potential implications for the nursing home industry. This decision makes Ozempic the first GLP-1 treatment option for this patient population, addressing a critical need given the high prevalence of CKD among diabetic nursing home residents.
Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated promising results in clinical trials. Novo Nordisk, the drug’s maker, reports that Ozempic reduced the risk of death from CKD and major cardiac events by 24% in people with diabetes. Furthermore, it lowered the risk of kidney failure and decreased the mortality risk from heart disease by approximately 5% in adults with both diabetes and CKD. These findings suggest a potential for improved health outcomes and quality of life for nursing home residents with these conditions.
“With this new indication, Ozempic stands out uniquely as the most broadly indicated GLP-1 RA in its class,” said Anna Windle, PhD, senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk. This expanded indication positions Ozempic as a key player in addressing the rising prevalence of cardiovascular-kidney-metabolic (CKM) syndrome, a condition affecting roughly one in three adults in the US, according to the American Heart Association.
The high correlation between type 2 diabetes and CKD is particularly relevant to the nursing home setting. Novo Nordisk estimates that approximately 40% of individuals with type 2 diabetes also have CKD. Considering that type 2 diabetes affects roughly 37 million adults in the US, as reported by the company, the impact of this approval could be substantial.
This development presents both opportunities and challenges for nursing homes. While Ozempic’s potential benefits for managing diabetes and CKD are encouraging, nursing home staff will need to be adequately trained on its administration and potential side effects. Integrating this new treatment into existing care protocols and ensuring accessibility for eligible residents will be crucial. Moreover, the cost-effectiveness of Ozempic and its impact on overall healthcare expenditures within the nursing home setting will need careful consideration. As the industry grapples with workforce challenges, educating staff on new medications and treatment protocols adds another layer of complexity. The Skilled Care Journal will continue to monitor the impact of this FDA approval and provide updates to the nursing home industry.